EUCTR2005-002038-36-IT进行中（未招募）不适用
A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson s disease dementia or dementia with Lewy Bodies - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female, out-patients of at least 50 years of age Written informed consent must be obtained from the patient or a legally acceptable representative if applicable and if different from the responsible caregiver and the responsible caregiver The patient has a current diagnosis of Parkinson s disease according to the clinical diagnostic criteria of the United Kingdom Parkinson s Disease Society Brain Bank and a current diagnosis of Parkinson s disease Dementia according to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders code 294.1 or the patient has a current diagnosis of DLB according to the third report of the DLB consortium Mini Mental State Examination total score between 10 and 24 both inclusive Modified Hoehn Yahr score is between I to III inclusive while ON Female patient must be 2 years post-menopausal or surgically sterile
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
- •Male or female, out-patients of at least 50 years of age Written informed consent must be obtained from the patient or a legally acceptable representative if applicable and if different from the responsible caregiver and the responsible caregiver The patient has a current diagnosis of Parkinson s disease according to the clinical diagnostic criteria of the United Kingdom Parkinson s Disease Society Brain Bank and a current diagnosis of Parkinson s disease Dementia according to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders code 294.1 or the patient has a current diagnosis of DLB according to the third report of the DLB consortium Mini Mental State Examination total score between 10 and 24 both inclusive Modified Hoehn Yahr score is between I to III inclusive while ON Female patient must be 2 years post-menopausal or surgically sterile
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any patient who meets one or more of the following criteria cannot be included in the study 1. Patients with evidence of any neurodegenerative disease other than PDD/DLB or other serious neurological disorders including, but not limited to Alzheimer s disease, frontotemporal dementia, vascular dementia probable or possible according to NINDS-AIREN criteria ; Huntington s disease, Progressive Supra nuclear Palsy, Multiple System Atrophy, Cortico Basal Degeneration, major cortical stroke or history of repeated strokes with stepwise progression of parkinsonian features, major or repeated head trauma, primary or secondary cerebral neoplasia, cerebral infection and normal pressure hydrocephalus. 2. Patients with a recent history of within 3 months of screening or currently untreated B12 or folate deficiency, which is considered clinically significant. 3. Patients with history of brain surgery or history of/current deep brain stimulation. 4. Patients with history of exposure to toxins or other drugs e.g. dopamine antagonists , which could account for the symptoms of parkinsonism. 5. Patients with a current diagnosis according to DSM-IV-TR of amnestic disorders, schizophrenia or schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, or post-traumatic stress disorder. Patients may be included if symptoms of major depression are treated and have been stable for 3 months . 6. Patients with evidence of clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease that could interfere with the study results. Patients with controlled diabetes, or patients with controlled hypertension, or right bundle branch block complete or partial may be included in the study. Patients with thyroid disease may also be included in the study, provided they are euthyroid. . 7. Patients with a systolic blood pressure while sitting greater than 180 mm/Hg, or less than 90 mm/Hg, or a diastolic blood pressure while sitting greater than 100 mm/Hg, or less than 50 mm/Hg at the Screening or Baseline visits. 8. Patients with history of seizures or known predisposing factors for epilepsy. 9. Patients with a history of severe drug allergy, or hypersensitivity, or patients with known hypersensitivity to memantine, amantadine, rimantidine or lactose. 10. Patients with an active oncological disease haematological or solid tumour within 5 years. Patients with local dermatological tumours such as basal or squamous cell carcinoma may be included if stable. 11. Patients with a known or suspected history within the past 5 years of alcoholism or drug abuse. 12. Patients who have taken AChEIs within 6 weeks prior to screening. AChEIs are not allowed during the course of the study. 13. Patients who are currently receiving memantine, or have taken memantine within the last 6 months prior to screening. 14. Patients who are taking, or have taken, any disallowed concomitant medications as defined in Appendix II that cannot be discontinued or switched to a permissible alternative, according to the timelines provided in Appendix II. 15. Patients who have been in an investigational drug study, or who have received treatment with an investigational drug within 30 days or 5 half-lives, whichever is longer of the screening visit. 16. The patient or caregiver, in the opinion of the investigator, is unlikely to comply with the clinical study;
- •Any patient who meets one or more of the following criteria cannot be included in the study 1. Patients with evidence of any neurodegenerative disease other than PDD/DLB or other serious neurological disorders including, but not limited to Alzheimer s disease, frontotemporal dementia, vascular dementia probable or possible according to NINDS-AIREN criteria ; Huntington s disease, Progressive Supra nuclear Palsy, Multiple System Atrophy, Cortico Basal Degeneration, major cortical stroke or history of repeated strokes with stepwise progression of parkinsonian features, major or repeated head trauma, primary or secondary cerebral neoplasia, cerebral infection and normal pressure hydrocephalus. 2. Patients with a recent history of within 3 months of screening or currently untreated B12 or folate deficiency, which is considered clinically significant. 3. Patients with history of brain surgery or history of/current deep brain stimulation. 4. Patients with history of exposure to toxins or other drugs e.g. dopamine antagonists , which could account for the symptoms of parkinsonism. 5. Patients with a current diagnosis according to DSM-IV-TR of amnestic disorders, schizophrenia or schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, or post-traumatic stress disorder. Patients may be included if symptoms of major depression are treated and have been stable for 3 months . 6. Patients with evidence of clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease that could interfere with the study results. Patients with controlled diabetes, or patients with controlled hypertension, or right bundle branch block complete or partial may be included in the study. Patients with thyroid disease may also be included in the study, provided they are euthyroid. . 7. Patients with a systolic blood pressure while sitting greater than 180 mm/Hg, or less than 90 mm/Hg, or a diastolic blood pressure while sitting greater than 100 mm/Hg, or less than 50 mm/Hg at the Screening or Baseline visits. 8. Patients with history of seizures or known predisposing factors for epilepsy. 9. Patients with a history of severe drug allergy, or hypersensitivity, or patients with known hypersensitivity to memantine, amantadine, rimantidine or lactose. 10. Patients with an active oncological disease haematological or solid tumour within 5 years. Patients with local dermatological tumours such as basal or squamous cell carcinoma may be included if stable. 11. Patients with a known or suspected history within the past 5 years of alcoholism or drug abuse. 12. Patients who have taken AChEIs within 6 weeks prior to screening. AChEIs are not allowed during the course of the study. 13. Patients who are currently receiving memantine, or have taken memantine within the last 6 months prior to screening. 14. Patients who are taking, or have taken, any disallowed concomitant medications as defined in Appendix II that cannot be discontinued or switched to a permissible alternative, according to the timelines provided in Appendix II. 15. Patients who have been in an investigational drug study, or who have received treatment with an investigational drug within 30 days or 5 half-lives, whichever is longer of the screening visit. 16. The patient or caregiver, in the opinion of the investigator, is unlikely to comply with the clinical study
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesEUCTR2005-002038-36-ATH. Lundbeck A/S200
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesPatients with Parkinson’s disease dementia or dementia with Lewy BodiesEUCTR2005-002038-36-FRH. Lundbeck A/S200
进行中（未招募）
不适用
Study of the efficacy and safety of memantine in patients with Parkinson?s disease dementia or dementia with Lewy BodiesParkinson?s disease dementia or dementia with Lewy BodiesMedDRA version: 14.1Level: PTClassification code 10067889Term: Dementia with Lewy bodiesSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2005-002038-36-ESH. Lundbeck A/S200
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesEUCTR2005-002038-36-GRH. Lundbeck A/S200
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson’s disease dementia or dementia with Lewy BodiesEUCTR2005-002038-36-GBH. Lundbeck A/S200